Table 2 Effects of rosuvastatin and pitavastatin on serum lipid levels
Baseline | 4 weeks | p value | 12 weeks | p value | ||
|---|---|---|---|---|---|---|
TC (mg/dL) | Rosuvastatin | 232 (160-288) | 163 (126-209) | <0.0001 | 171 (125-206) | <0.0001 |
Pitavastatin | 249 (174-301) | 178 (111-215) | <0.0001 | 183 (118-252) | <0.0001 | |
LDL-C (mg/dL) | Rosuvastatin | 159 (103-216) | 83 (55-145) | <0.0001 | 88 (50-138) | <0.0001 |
Pitavastatin | 176 (117-240) | 106 (46-155) | <0.0001 | 98 (48-180) | <0.0001 | |
HDL-C (mg/dL) | Rosuvastatin | 56 (36-79) | 61 (40-90) | 0.07 | 63 (38-103) | 0.005 |
Pitavastatin | 60 (41-93) | 62 (41-125) | 0.14 | 63 (40-120) | 0.16 | |
TG (mg/dL) | Rosuvastatin | 164 (75-396) | 116 (70-211) | 0.002 | 110 (71-312) | 0.009 |
Pitavastatin | 169 (84-303) | 134 (61-316) | 0.01 | 121 (64-311) | 0.01 | |
Apo Al (mg/dL) | Rosuvastatin | 144 (106-172) | 151 (116-192) | 0.01 | 147 (116-234) | 0.004 |
Pitavastatin | 150 (119-203) | 149 (100-256) | 0.35 | 152 (94-257) | 0.19 | |
Apo B (mg/dL) | Rosuvastatin | 116 (76-159) | 75 (52-106) | <0.0001 | 77 (49-103) | <0.0001 |
Pitavastatin | 132 (86-176) | 87 (43-111) | <0.0001 | 88 (43-143) | <0.0001 | |
Apo E (mg/dL) | Rosuvastatin | 4.7 (3.6-7.6) | 3.7 (2.6-5.2) | <0.0001 | 3.6 (2.4-4.6) | <0.0001 |
Pitavastatin | 5.4 (3.3-11.9) | 4.3 (2.2-8.0) | <0.0001 | 4.3 (2.7-9.7) | <0.0001 |